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Reflection & Reaction
Global democratic consensus on neuropathological disease criteria
On July 10 and 11, 2002, a group of
experts in Parkinson’s disease attended
a satellite meeting of the 7th European
Congress of Neuropathology in
London, UK, and agreed on a core
definition of the histopathological
phenotype of Parkinson’s disease,
which takes into account recent
developments in the field (eg, 
-synuclein immunohistochemistry)
but essentially abandons many
conventional criteria as they are no
longer sufficient. This definition and
comments can be viewed at
http://www.ICDNS.org.
It rapidly became clear during the
discussions at this meeting—and
subsequently at the European Congress
in Helsinki, Finland (July 13–16,
2002)—that a thoroughly democratic
voting system on disease criteria, which
uses the worldwide web to provide
global access to all qualified
diagnosticians, would represent a
fundamental breakthrough. The plan
was adopted, therefore, to publish
diagnostic criteria for all recognised
neuropathological diseases on the web,
where the global community of
neuropathologists can judge them.
Acceptance should be facilitated greatly
by the fact that no named individual or
national group is leading the initiative.
Instead, existing classifications will be
“translated” into a generic format
avoiding personal as well as
institutional names to ensure
consistency of terminology between
related disease processes.
The majority of neurological
diseases are currently defined on the
basis of their histopathological pheno-
type. However, molecular definitions
are likely to apply even to 
common, genetically heterogeneous, or
“complex” neurological disorders, such
as Parkinson’s and Alzheimer’s disease.
Molecular definitions are advantageous
as they provide a rationale for precisely
targeted, individualised therapies that
are most cost effective.
Degenerative diseases are among
the most common neurological
disorders—many are related to ageing
and are late in onset. Consequently, it is
expected that the prevalence of these
diseases will rise significantly over the
next two decades in the western
population, followed by a similar,
although less dramatic, increase in
other populations.
An important development with
regard to disease classification concerns
the increasingly quantitative nature of
biomedical research. Although the
single hypothesis-driven scientific
approach has been widely used during
the past few decades, “exploration
science” is gaining predominance with
the introduction of high-throughput
analysis methods based on microarrays.
This approach is employed widely 
in genomic, transcriptomic, and
proteomic research and is beginning to
be used in clinical settings.
Quantitative definitions of histo-
pathological phenotypes could be
linked to array data sets and combined
with imaging and clinical parameters to
produce a multidimensional data space
from which binary codes representing
“signatures of disease” can be extracted.
The implementation of these exciting
new opportunities into the daily
practice of neurologists and other
clinical neuroscientists will benefit
greatly from global consensus on key
criteria that are used globally for
making a histophenotypical diagnosis.
However, it is surprising that an
international consensus on neuro-
pathological disease criteria does not
exist, except in the field of brain
tumours where the WHO backs an
existing histological classification.
Consequently, the WHO has been
asked to do the same for the neuro-
degenerative diseases group but the
problem clearly extends to other
diseases of the nervous system as well.
The proposed way of developing
such criteria is for recognised experts
to prepare core definitions that
are published anonymously online.
Diagnosticians can then suggest modifi-
cations, which are signed and dated. All
users have to register to confirm their
identity. Each comment—if not
withdrawn by the author before an
agreed deadline—will become part of
the history of a disease definition. No
opinion will be ignored provided it
comes from a qualified colleague as
confirmed by the respective disease
“moderator”. When a consensus has
been reached, a vote will be taken to
accept a published version of a
classification or diagnostic criteria.
Both core definitions and comments
can be used immediately for diagnostic
purposes as outlined in the 
guidance section of the website
(http://www.ICDNS.org).
Core definitions are expected to
receive both positive and negative votes.
Although the details remain to be
worked out, the immediate advantage
of such a scheme is that core definitions
can be updated in line with
developments in the field either by
expert groups (eg, during specialist
meetings) or individuals—both have to
be approved by a democratic poll on the
web. This concept was discussed and
backed by the signatories below. Terms
of reference have been posted and are
now open for discussion at
http://www.ICDNS.org.
For the first time, a global consensus
on histopathological diagnostic criteria
is within reach. Neighbouring pro-
fessional disciplines, such as neurology,
neurosurgery, neuroradiology, and
psychiatry, are strongly encouraged to
engage in similar activities. This should
result in a common basis for correlative
molecular work which will be of utmost
importance in the future.
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